Important Notice for Investors in Applied Therapeutics, Inc. Before February 2025 to Assert Your Rights

Investors Urged to Act: Important News for Applied Therapeutics Shareholders

In an important announcement, The Gross Law Firm has advised shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT) to reach out before February 18, 2025, to discuss their rights concerning the company's recent controversies. This notice particularly addresses those who purchased shares in the specified class period: between January 3, 2024, and December 2, 2024.

Background on the Recent Developments

On November 27, 2024, Applied Therapeutics made headlines when it revealed it had received a Complete Response Letter (CRL) from the FDA regarding its lead drug candidate, govorestat. This CRL indicated that the FDA had reviewed the New Drug Application (NDA) but found deficiencies that prevented approval in its current form. The news led to a steep decline in the company's stock price, dropping from $10.21 per share down to as low as $1.29 per share within a week, representing a shocking decrease of over 80%.

Following the announcement of the CRL, the situation worsened when Applied Therapeutics disclosed a 'warning letter' from the FDA, shedding light on severe clinical trial issues. This development drew further concern from investors, leading to additional declines in the stock price.

The Class Action Opportunity

In light of these events, shareholders are encouraged to consider participation in a class action lawsuit. Although being appointed as a lead plaintiff is not required for recovery, it provides an opportunity for affected investors to assert their rights collectively. Interested shareholders can register via the Gross Law Firm's dedicated webpage, where they will also receive regular updates on the case's progress.

The deadline to seek lead plaintiff status in this class action is set for February 18, 2025. It’s essential for shareholders to act promptly to ensure their voices are heard and their rights protected. Because of the complexities involved, shareholders are reminded that there is no cost to participate.

Why Choose The Gross Law Firm?

The Gross Law Firm is recognized nationally for its commitment to shareholder rights and corporate accountability. The firm's mission is to safeguard investors against deceit, fraud, and illegal business practices, ensuring that firms operate with transparency and responsibility. Their team is dedicated to advocating for public investors who have suffered losses due to misleading statements or omissions that artificially inflated stock prices.

If you purchased shares of Applied Therapeutics within the designated class period, don’t hesitate to reach out to The Gross Law Firm. By asserting your rights now, you join fellow shareholders in pursuing justice and potential recovery for losses incurred.

Contact Details

To take action, shareholders can contact The Gross Law Firm directly at:

- Email: info@grosslawfirm.com
- Phone: (646) 453-8903

It is crucial to remain proactive and informed, as the landscape seems volatile for Applied Therapeutics and its investors. Register today to ensure you stay updated and supported as this case unfolds.